ASX:CSLBiotechs
CSL (ASX:CSL) Valuation Check After Outlook Cut And Cancelled Seqirus Spin Off
CSL (ASX:CSL) is back in focus after it cut its fiscal 2026 revenue growth outlook and scrapped the planned Seqirus spin off, following weaker U.S. influenza vaccination rates and slower plasma recovery.
See our latest analysis for CSL.
The share price has been under pressure since the October outlook cut, with a 30 day share price return of 6.32% and a 90 day share price return of 16.01%. This contributed to a 1 year total shareholder return of 38.14% as sentiment toward CSL’s growth profile...